From development to patient delivery, meet the experts and discover the solutions that can help move your radiopharmaceutical projects forward.

Booth 528 | Vienna | October 17–21

Book a meeting
Explore what we’ll showcase

A promising radiopharmaceutical is only the beginning.

Bringing a radiopharmaceutical from concept to patients is not a single challenge. It’s a sequence of them and they evolve rapidly.

Early on

Speed is critical. Rapid access to R&D-grade API precursors, radiochemistry development, and data you can trust. This is where months are won or lost.

Later

New challenges emerge: reproducibility, automation, GMP manufacturing, multisite transfer, regulatory dossiers, industrial scalability.

As a radiopharmaceutical team, you don’t need another supplier. You need a partner able to carry the next critical steps in your development journey.

That’s Trasis’s added value: we walk with you through your entire journey, activating the right solution as your needs grow.

Whether your journey starts with an R&D-grade API precursor, a radiolabeling process, an automated synthesis platform, GMP manufacturing capabilities, regulatory support, or a complete industrialization strategy, Trasis provides the expertise, technologies, and integrated services needed to keep your program moving forward.

From early development to commercialization, we help bridge the gap between scientific innovation and patient impact.

Because success in radiopharmaceutical development is not about solving one problem. It’s about having the right partner at every stage.

This October at EANM, we’ll open up the full roadmap: the technologies, the CDMO capabilities and the teams behind each stage.

Until then, we’re publishing it here, one stage at a time: the real challenge it creates, and how we help solve it.

Developing the next generation of radiopharmaceuticals? Let’s talk.

Book a moment with our team to discuss your project.

We’ll help you find the tailored solution to bring it to the next level.

Book a meeting

Take a look at our program below, then come find us on booth 528.

Different challenges. One partner.

Precursor > Radiochemistry > Analytics > Automation > GMP manufacturing > Cold kits > Sterile drug product > Industrialisation > Market authorization

R&D

1

Challenge

Candidate screening & selection
Early feasibility

Trasis solution

R&D grade API precursors
Custom synthesis, rapid delivery
Cost-effective development
Radiolabelling feasibility

Preclinical

2

Challenge

Animal proof of concept
Biodistribution
Translational data
Go / No-Go decisions

Trasis solution

R&D grade API precursors
Radiochemistry development
Analytical development
Tox-study batch supply

Phase I

3

Challenge

First-in-human
Clinical proof of concept
Early clinical data
Investor and partner interest

Trasis solution

GMP grade API precursors
Manual or automated synthesis
Analytical method development
Clinical manufacturing support

Phase II

4

Challenge

Multisite deployment
Process reproducibility
Scale-up readiness
Operational robustness

Trasis solution

GMP grade API precursors
Automation platforms and synthesis sets (consumables)
Robust, transferable processes

Phase III

5

Challenge

Process robustness
Commercial readiness preparation
Large-scale deployment

Trasis solution

Robust API precursor supply at scale
Automated production
QC implementation and QC standardisation
Sterile solution development (if required)
Cold kit development and manufacturing

Marketing Authorization, Industrialization & Commercial Deployment

6

Challenge

Regulatory approval
High-volume manufacturing
Supply continuity
Global deployment
Reliability and reproducibility

Trasis solution

Large-scale API precursor manufacturing
Cold kit and sterile fill-finish
Standardized QC deployment
DMF / AMF support
Packaging and distribution
After-sales technical support

Continuous support throughout the development lifecycle

✓
Continuous quality

✓
Regulatory support (DMF / ASMF)

✓
Technical support

Discover the full range of Trasis products

Explore our contributions at EANM

A multi-radionuclide automated platform for small molecules and peptides radiolabelling

EJNMMI Radiopharmacy & Chemistry, 2026

Julien Masset

Presentation Number: OP-153

Session Number: 504

Session Type: M2M Track

Session Title: M2M Track – TROP Session – Radiopharmaceutical Sciences Committee: Radiosynthesis and radionuclide production

Date: Sunday, October 18, 2026

Time: 3:00 PM – 4:30 PM

Hall: Hall E2

A multi-radionuclide platform for immunoconjugate radiolabeling

e-Poster Presentation Session

Julien Masset

Presentation Number: EPS-088

Session Number: 709

Session Type: e-Poster Presentation Session

Session Title: The science of radiopharmaceutical preparation

Date: Monday, October 19, 2026

Time: 8:00 AM – 9:30 AM

Hall: Hall G2

Comparative Study between QC1-Automated System and Standard Procedures for Radiopharmaceuticals: A Focus on [¹⁸F]DPA-714

Leo Pineda

Abstract: # 2133

e-Poster Session Number: EP-60

Join our EANM26 side events!

Connecting with our community: What’s standing between your molecule and the patient?
Three experts share practical answers on development, automation and dose safety.

More info

Join our EANM26 side events - Vienna, October 18 & 19

Join our EANM26 side events - Vienna, October 18 & 19

Booth 528 | Vienna | October 17–21

Book a meeting

Meet Trasis at EANM 2026